Wall Street analysts expect ICU Medical, Incorporated (NASDAQ:ICUI) to report sales of $309.10 million for the current quarter, according to Zacks Investment Research. Two analysts have provided estimates for ICU Medical’s earnings. The highest sales estimate is $313.00 million and the lowest is $305.20 million. ICU Medical posted sales of $360.46 million during the same quarter last year, which would indicate a negative year over year growth rate of 14.2%. The firm is expected to announce its next earnings report on Thursday, August 8th.
According to Zacks, analysts expect that ICU Medical will report full year sales of $1.26 billion for the current year, with estimates ranging from $1.25 billion to $1.27 billion. For the next financial year, analysts forecast that the business will report sales of $1.30 billion, with estimates ranging from $1.30 billion to $1.31 billion. Zacks Investment Research’s sales averages are an average based on a survey of sell-side analysts that cover ICU Medical.
ICU Medical (NASDAQ:ICUI) last released its quarterly earnings results on Thursday, May 9th. The medical instruments supplier reported $2.35 EPS for the quarter, beating analysts’ consensus estimates of $1.96 by $0.39. ICU Medical had a return on equity of 13.70% and a net margin of 4.04%. The firm had revenue of $330.93 million for the quarter, compared to analyst estimates of $318.97 million. During the same quarter in the previous year, the company posted $2.26 EPS. The business’s revenue was down 11.0% on a year-over-year basis.
In related news, VP Virginia Ruth Sanzone sold 5,277 shares of the company’s stock in a transaction dated Thursday, March 7th. The stock was sold at an average price of $232.31, for a total transaction of $1,225,899.87. Following the sale, the vice president now owns 13,167 shares in the company, valued at approximately $3,058,825.77. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, COO Christian B. Voigtlander sold 5,348 shares of the company’s stock in a transaction dated Tuesday, May 14th. The shares were sold at an average price of $227.59, for a total value of $1,217,151.32. Following the sale, the chief operating officer now owns 4,732 shares in the company, valued at approximately $1,076,955.88. The disclosure for this sale can be found here. Insiders sold a total of 12,318 shares of company stock worth $2,839,576 in the last quarter. Corporate insiders own 11.40% of the company’s stock.
Several institutional investors have recently made changes to their positions in the stock. Janus Henderson Group PLC boosted its position in shares of ICU Medical by 1.2% during the 1st quarter. Janus Henderson Group PLC now owns 2,685,713 shares of the medical instruments supplier’s stock valued at $642,772,000 after purchasing an additional 31,946 shares in the last quarter. BlackRock Inc. boosted its position in shares of ICU Medical by 0.8% during the 1st quarter. BlackRock Inc. now owns 1,485,971 shares of the medical instruments supplier’s stock valued at $355,639,000 after purchasing an additional 12,345 shares in the last quarter. Vanguard Group Inc boosted its position in shares of ICU Medical by 12.0% during the 3rd quarter. Vanguard Group Inc now owns 1,483,501 shares of the medical instruments supplier’s stock valued at $419,459,000 after purchasing an additional 158,798 shares in the last quarter. JPMorgan Chase & Co. boosted its position in shares of ICU Medical by 1.8% during the 1st quarter. JPMorgan Chase & Co. now owns 517,703 shares of the medical instruments supplier’s stock valued at $123,902,000 after purchasing an additional 9,021 shares in the last quarter. Finally, FMR LLC boosted its position in shares of ICU Medical by 91.1% during the 4th quarter. FMR LLC now owns 417,787 shares of the medical instruments supplier’s stock valued at $95,937,000 after purchasing an additional 199,185 shares in the last quarter. Institutional investors own 92.90% of the company’s stock.
Shares of NASDAQ ICUI traded down $4.37 during trading on Thursday, reaching $224.59. The company had a trading volume of 168,040 shares, compared to its average volume of 221,757. ICU Medical has a 12 month low of $210.94 and a 12 month high of $321.70. The firm has a market capitalization of $4.63 billion, a PE ratio of 29.13 and a beta of 0.69.
About ICU Medical
ICU Medical, Inc develops, manufactures, and sells medical devices used in vascular therapy, critical care, and oncology applications worldwide. It offers infusion therapy products comprising a tube running from a bottle or plastic bag containing a solution to a catheter inserted in a patient's vein.
Recommended Story: What is Green Investing?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ICU Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICU Medical and related companies with MarketBeat.com's FREE daily email newsletter.